3 results
Study IM011-077 is a Phase 2 randomized, open-label, multicenter clinical study designed to assess the safety and tolerability, efficacy and biomarker response of deucravacitinib 6 mg BID (twice daily) in subjects with moderate to severe Ulcerative…
Main objective: The main objective of this open-label, single arm study is to further characterize the safety, tolerability and effectiveness profile of olesoxime in SMAThe primary safety objective for this study is as follows:To evaluate the safety…
The objective of this first-in-human study is to evaluate the safety, feasibility and efficacy of Re-Cellularization via Electroporation Therapy (ReCET) by the (Endogenex system) combined with (GLP-1 receptor agonist) in subjects with insulin…